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Abstract
In contrast to most developed countries, most patients with primary
hyperparathyroidism in Brazil are still symptomatic at diagnosis.
However, we have been observing a change in this pattern, especially
in the last few years. We evaluated 104 patients, 77 females and 27
males aged 11-79 years (mean: 54.4 years), diagnosed between 1985
and 2002 at a University Hospital. Diagnosis was made on the basis of
clinical findings and of high total and/or ionized calcium levels, high
or inappropriate levels of intact parathyroid hormone and of surgical
findings in 80 patients. Patients were divided into three groups, i.e.,
patients diagnosed from 1985 to 1989, patients diagnosed from 1990
to 1994, and patients diagnosed from 1995 to 2002. The number of
new cases diagnosed/year increased from 1.8/year in the first group to
6.0/year in the second group and 8.1/year in the third group. The first
group comprised 9 patients (mean serum calcium ± SD, 13.6 ± 1.6 mg/
dl), 8 of them (88.8%) defined as symptomatic. The second group
comprised 30 patients (mean calcium ± SD, 12.2 ± 1.63 mg/dl), 22 of
them defined as symptomatic (73.3%). The third group contained 65
patients (mean calcium 11.7 ± 1.1 mg/dl), 34 of them symptomatic
(52.3%). Patients from the first group tended to be younger (mean ±
SD, 43.0 ± 15 vs 55.1 ± 14.4 and 55.7 ± 17.3 years, respectively) and
their mean serum calcium was significantly higher (P < 0.05). All of
symptomatic patients independent of group had higher serum calcium
levels (12.4 ± 1.53 mg/dl, N = 64) than asymptomatic patients (11.4 ±
1.0 mg/dl, N = 40). Our data showed an increase in the percentage of
asymptomatic patients over the years in the number of primary
hyperparathyroidism cases diagnosed. This finding may be due to an
increased availability of diagnostic methods and/or to an increased
awareness about the disease.
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Primary hyperparathyroidism (PHP) is a
hypercalcemic disease due to an abnormally
increased secretion of parathyroid hormone
(PTH) from one or more parathyroid glands.
The hallmark of this condition is the pres-
ence of high levels of serum calcium and
high or inappropriate levels of PTH. PHP is
a common disease and in 1999, about 22,000
individuals had a discharge diagnosis of PHP
in the United States, and PHP was the first-
listed diagnosis in 5000 of them (1). The
incidence of hospitalization for PHP was 8.0
per 100,000 per year, counting “all listed”
diagnoses, and 1.8 per 100,000 counting
only the first-listed diagnoses (2). In Europe,
the introduction of serum calcium screening
in the early 1970’s made possible the identi-
fication of a large number of “asymptomat-
ic” patients (3). This led also to a 5-fold
increase in the apparent incidence of PHP
for the identification of patients who where
never diagnosed before (3). As soon as this
cohort of usually asymptomatic patients was
identified (catch up-effect) a decline in the
rate of diagnosis of new cases was antici-
pated from the 1970’s to the 1990’s (3). In
the most recent and accurate study, a 21/
1000 prevalence of PHP was found in women
aged 55-75 years, which is equivalent to a 3/
1000 prevalence in the general population
(3). The incidence of PHP rises with age,
from nonreportable at ages less than 45 years
to 11.9 per 100,000 at the ages of 45-64
years and to 40.9 per 100,000 among those
aged 65 years and over in the United States
(1). PHP is more common in women, with a
70% higher overall hospitalization rate
among women than men (12.2 vs 7.2 per
100,000 per year) in the United States in
1999 (2). PHP is caused by a solitary ad-
enoma in almost 80% of cases; hyperplasia
of all four glands is seen in 15 to 20% and
carcinoma is a very rare cause of PHP, ac-
counting for less than 0.5% of the cases (4).
When PHP was first described in the 1930’s,
it was considered to be a rare disease and its
clinical presentation was that of a disabling
condition, with predominance of bone symp-
toms. Nowadays, in the United States, most
patients with PHP have few or no symptoms
at diagnosis (5) and calcium levels are not
usually higher than 1 mg/dl above the upper
normal limits (6). However, in a previous
publication we showed a higher incidence of
symptomatic patients by the time of diagno-
sis among Brazilian patients (7). These dif-
ferences in clinical presentation of PHP might
be related to several causes, including aware-
ness about the disease, availability of labo-
ratory resources and vitamin D status.
The purpose of the present study was to
evaluate changes in clinical and laboratory
presentation of PHP at our University Hos-
pital. The study was retrospective. Reports
of 104 patients with PHP diagnosed between
1985 and 2002 were reviewed. There were
77 (74%) females and 27 (25.9%) males
(2.8:1 ratio). Age ranged from 11 to 79
years, with a mean age at diagnosis of 54.4
years. PHP was diagnosed on the basis of the
finding of high levels of total and/or ionized
calcium and high or inappropriate PTH lev-
els. In our Endocrinology unit, calcium meas-
urements are performed in a systematic way
and are responsible for the diagnosis of
asymptomatic PHP. However, some patients
were referred to our unit after they had shown
hypercalcemia in a laboratory investigation
of osteoporosis and/or kidney stones. In 80
patients the diagnosis was confirmed by sur-
gery. Patients did not undergo surgery if
they presented co-morbidities and a high
surgical risk or if they refused surgical treat-
ment. Based on their clinical presentation,
patients were classified as symptomatic or
asymptomatic. We defined as symptomatic
patients who presented typical bone disease
(we did not consider osteopenia as a typical
bone disease), hypercalcemic metabolic syn-
drome, and/or recurrent stone disease. Pa-
tients were divided into three groups accord-
ing to the year of diagnosis: the first in-
cluded patients diagnosed from 1985 to 1989,
the second patients diagnosed from 1990 to
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1994, and the third patients diagnosed from
1995 to 2002. These groups were defined
according to available laboratory methods
for PHP diagnosis: ionized calcium meas-
urements were available after 1990 and in-
tact PTH measurements were available after
1994. Up to 1993 PTH was measured using
an amino-terminal specific radioimmunoas-
say (8); from 1994 on, intact PTH was meas-
ured using an immunofluorometric assay
(reference values: 10-70 pg/ml) (9); ionized
calcium (available only from 1990 on) was
measured with an ion-specific electrode
(AVL 9180 Electrolyte Analyzer, Roswell,
GA, USA; reference values: 1.12-1.32 mmol/
l), and total calcium by colorimetric assays
(reference values: 8.5-10.5 mg/dl). Mean
PTH values considered only intact PTH.
Data were analyzed by the unpaired t-test,
unpaired t-test with Welsh correction and by
ANOVA, as appropriate, with the level of
significance set at P < 0.05.
In 71 patients we measured both total and
ionized calcium, and a correlation (Spear-
man) of r = 0.782 (P < 0.05) was obtained.
The first group of patients (1985-1989) com-
prised 9 patients (mean serum calcium of
13.6 ± 1.6 mg/dl), 8 of them (88.8%) defined
as symptomatic; all underwent surgery. The
second group of patients (1990-1994) in-
cluded 30 patients (mean serum calcium of
12.2 ± 1.63 mg/dl), 22 of them (73.3%)
classified as symptomatic; 27 of these pa-
tients were operated upon (90%). The third
group (1995-2002) comprised 65 patients
(mean serum calcium of 11.7 ± 1.1 mg/dl),
34 (52.3%) classified as symptomatic; 44
were operated upon (67.6%). The number of
new cases increased from 1.8/year in the
first group to 6.0/year in the second group
and 8.1/year in the third group. Among the
80 patients operated upon, surgical findings
showed adenomas in 75%, double adenoma
in 1.2%, hyperplasia in 11.2%, and carcino-
mas in 7.5%. Patients from the first group
tended to be younger (43.0 ± 15.07 years)
than patients of the second group (55.1 ±
14.47 years, P = 0.0357) and the third group
(55.7 ± 17.13 years, P = 0.0382), and their
mean total calcium levels were significantly
higher (P < 0.05). All symptomatic patients
had higher total calcium levels (12.43 ± 1.53
mg/dl) than asymptomatic ones (11.43 ± 1.0
mg/dl, P = 0.0014); the total PTH levels
were also higher in the symptomatic patients
(N = 35, 463.8 ± 572.6 pg/ml) compared to
the asymptomatic ones (N = 38, 213.8 ±
276.3 pg/ml; P = 0.0233).
It is well known that the clinical features
of PHP are related to the continuous action
of PTH and correlate with the degree of
hypercalcemia. The initial presentation of
PHP has changed over the years in devel-
oped countries, with a marked increase in
number of patients with few or no symp-
toms. The reasons for this tendency may be
related to more widespread use of screening
tests, especially serum calcium measure-
ments. Data from developing countries indi-
cate a lower number of new cases who mainly
consist of patients with a dramatic clinical
and laboratory presentation by the time of
diagnosis (7,10,11). The data showed a
changing pattern. The number of new cases
of asymptomatic patients increased over the
years (Figure 1), and calcium levels at the
time of diagnosis were lower. In addition,
among asymptomatic subjects, calcium and
PTH levels were lower than among sympto-
matic ones. All of these findings reflect an
Figure 1. Percentage of sympto-
matic and asymptomatic hyper-
parathyroidism patients diag-
nosed from 1985 to 2002 at our
University Hospital. Data are re-
ported for 64 symptomatic and
40 asymptomatic patients.
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earlier diagnosis. Some reasons for this might
be related to an increased availability of
diagnostic methods such as those for ionized
calcium and intact PTH measurements. It is
interesting to note that, after observing all of
these changes, we have been paying more
attention to the disease and we have been
searching for these asymptomatic PHP pa-
tients. Furthermore, it is important to point
out that, as part of the staff of a Medical
School, we have been discussing these find-
ings with other departments, contributing to
an increasing awareness about the disease.
We have observed a higher incidence of
PHP patients with carcinomas (7.5%) than
reported in literature (12). The reasons for
this apparent higher incidence may be as
follows: first, we believe we do not have
more PHP patients with carcinomas than
other countries in absolute numbers; in fact,
we are still misdiagnosing asymptomatic
patients. Therefore, the proportions of carci-
noma are apparently higher than expected.
A second reason for this higher incidence is
related to the clinical profile of PHP ob-
served in the past. We had many sympto-
matic patients with dramatic bone disease,
and the probability of finding patients with
carcinomas in a group with these character-
istics is higher.
The changing spectrum of PHP over the
world has led to a controversial idea, i.e., the
existence of normocalcemic PHP. The pa-
tients with this condition would have no
symptoms and would show high PTH levels
with normal serum calcium, and would be
considered to be in the early stages of the
disease (13). However, some questions re-
main regarding the vitamin D status of these
patients. Low levels of vitamin D are com-
mon in elderly people (14) and it is still
difficult to determine appropriate values of
vitamin D in order to suppress PTH levels in
these subjects. Considering the high inci-
dence of PHP in patients aged 60 years or
older, it might be difficult to define in some
cases presenting high levels of PTH with
normal serum calcium whether this is due to
autonomous parathyroid stimuli or to a re-
sponse to low levels of vitamin D. The asso-
ciation of higher PTH levels in PHP patients
with vitamin D deficiency (10,15-17) raises
the possibility that the regional differences
in clinical presentation may also be depend-
ent on a higher prevalence of vitamin D
deficiency. Also, the inverse correlation be-
tween vitamin D status and parathyroid ad-
enoma weight may be the explanation for
the more severe cases described in vitamin
D-deficient areas (18).
Our data show an increase in the number
of cases diagnosed in the last years involv-
ing not only symptomatic patients, but also
asymptomatic ones. These findings may be
due to several reasons, the most probable
ones being the increased awareness about
PHP and the more widespread availability of
diagnostic tests to detect the presence of
PHP.
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